Literature DB >> 34379085

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease.

Thomas A Ollila1,2, Shaolei Lu1,3, Rebecca Masel1, Adam Zayac1,2, Kimberly Paiva3, Ralph D Rogers1,4, Adam J Olszewski1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34379085      PMCID： PMC8358793          DOI： 10.1001/jamaoncol.2021.4381

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   33.006


× No keyword cloud information.
  29 in total

1.  Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

2.  How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.

Authors:  Antoni Ribas; Madhav V Dhodapkar; Katie M Campbell; Faith E Davies; Steven D Gore; Ronald Levy; Lee M Greenberger
Journal:  Blood Cancer Discov       Date:  2021-09-15

3.  Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.

Authors:  Ayse Ozdede; Okan Kadir Nohut; Zeynep Atli; Yeşim Tuyji Tok; Sabriye Guner; Erkan Yilmaz; Didar Ucar; Ugur Uygunoglu; Vedat Hamuryudan; Emire Seyahi
Journal:  Rheumatol Int       Date:  2022-07-02       Impact factor: 3.580

4.  Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.

Authors:  Michael A Thompson; Sigrun Hallmeyer; Veronica E Fitzpatrick; Yunqi Liao; Michael P Mullane; Stephen C Medlin; Kenneth Copeland; James L Weese
Journal:  J Patient Cent Res Rev       Date:  2022-07-18

Review 5.  A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.

Authors:  Maryam Noori; Shadi Azizi; Farhan Abbasi Varaki; Seyed Aria Nejadghaderi; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2022-07-12       Impact factor: 5.714

Review 6.  Vaccination for SARS-CoV-2 in Hematological Patients.

Authors:  Niccolò Riccardi; Marco Falcone; Dafna Yahav
Journal:  Acta Haematol       Date:  2022-02-25       Impact factor: 3.068

7.  Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2021-11-18       Impact factor: 5.732

8.  Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.

Authors:  Yanina Pasikhova; Austin R Morrison; Ju Hee Katzman; Misbahuddin Syed
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

9.  Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.

Authors:  Cinzia Borgogna; Riccardo Bruna; Gloria Griffante; Licia Martuscelli; Marco De Andrea; Daniela Ferrante; Andrea Patriarca; Abdurraouf Mokhtar Mahmoud; Valentina Gaidano; Monia Marchetti; Davide Rapezzi; Michele Lai; Mauro Pistello; Marco Ladetto; Massimo Massaia; Gianluca Gaidano; Marisa Gariglio
Journal:  Blood Cancer J       Date:  2022-01-18       Impact factor: 11.037

10.  COVID-19 vaccination and breakthrough infections in patients with cancer.

Authors:  A L Schmidt; C Labaki; C-Y Hsu; Z Bakouny; N Balanchivadze; S A Berg; S Blau; A Daher; T El Zarif; C R Friese; E A Griffiths; J E Hawley; B Hayes-Lattin; V Karivedu; T Latif; B H Mavromatis; R R McKay; G Nagaraj; R H Nguyen; O A Panagiotou; A J Portuguese; M Puc; M Santos Dutra; B A Schroeder; A Thakkar; E M Wulff-Burchfield; S Mishra; D Farmakiotis; Yu Shyr; J L Warner; T K Choueiri
Journal:  Ann Oncol       Date:  2021-12-24       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.